Clinical Trial Update: Long-term Extension of GTX-102 in Angelman Syndrome [Phase 3]

View source ↗

Summary

This notice reports a long-term extension study for GTX-102 in Angelman Syndrome, a Phase 3 trial that is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• GTX-102

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Angelman Syndrome | Phase 3 | Status: ENROLLING_BY_INVITATION